- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Consolidated Q3FY25 revenue for Balaji Amines stood at ₹321 crore, down from ₹356 crore in Q2FY25. EBITDA decreased to ₹54 crore with margins at 17%, compared to 20% in the previous quarter. Net profit was ₹31 crore, a decline from ₹41 crore in Q2, resulting in a diluted EPS of ₹10.24.
The company's total sales volume was 24,097 MT for Q3, dropping from 26,348 MT in Q2. Despite these challenges, Balaji Amines continues to progress with new projects expected to enhance production capacities, including Electronic Grade DMC and Propylene Glycol Pharma Grade, both anticipated to be commissioned by March 2025.
A significant expansion is planned for its subsidiary, Balaji Specialty Chemicals, with an investment of ₹750 crore into new products. This initiative received Mega Project status from the Maharashtra government. The outlook remains positive, with management indicating potential for improved margins as domestic demand recovers and capacity utilization increases, reinforcing their market position in the specialty chemicals sector.